Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Takes Action To Prevent Further Impurities After Sartans

Executive Summary

The EMA is launching an initiative aimed at preventing impurities in medicines and better handling cases where impurities do occur, following the agency’s experiences in dealing with sartans that contained nitrosamine impurities.

You may also be interested in...



Sartans Recalled In UK As Further Impurity Is Confirmed

Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.

Sartans Recalled In UK As Further Impurity Is Confirmed

Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.

EU Takes Lessons From Valsartan Crisis

EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB140302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel